Microtissue magic: 3D-printed tech for cell culture production 'degrades on demand'

By Flora Southey

- Last updated on GMT

Researchers at Brown University have developed a 3D printing technique which they say could be used to make cell cultures for biopharmaceutical production.

The researchers have reported their findings in micro-scale focused journal Lab on a Chip​ in a paper ​which explains how the temporary structures can be ‘degraded away on demand’ with a biocompatible chemical trigger. 

“We can attach polymers together to build 3D structures, and then gently detach them again under biocompatible conditions,” ​explained lead researcher Ian Wong.


The structures are made using a 3D printing technique called stereolithography, which links photoactive polymers together to create reversible bonds.

A computer-aided design system, in conjunction with an ultraviolet laser, traces patterns across the surface of a sodium alginate (a compound derived from seaweed) polymer solution, which causes the polymers to link together and form solid 3D structures.

“Conventional light-based 3D printing uses covalent crosslinking, which is static and irreversible,” ​Wong told us.

“The key innovation here is to use noncovalent (ionic) crosslinking, which enables stimuli-responsive, reversible biomaterial patterning,” ​he explained.

According to Wong, the team developed the technology with the use of an outdated stereolithography system purchased second-hand.

“We purchased an industrial light-based stereolithography system off eBay which dates back to the 1980s.”

“These systems are incredibly robust and their operation is completely open source, allowing us to easily “hack” them for biofabrication,” ​he explained.

Biopharmaceutical production

Wong told us the technology could be used by drug manufacturers to make intricate microtissues for biopharmaceutical production.

“This technology can 3D print biomaterials with well-controlled shapes and tunable degradation kinetics, which could be used for biofabrication of microtissues with perfusable, vascular-like channels.”

Further, the researchers said experiments showed the agent used to dissolve the 3D-printed structures had no appreciable toxicity to the cells

“These biomaterials could also be used for the controlled release of living cells or drugs,” ​Wong added.

Affordable seaweed

Wong told us the technology is affordable, and he expects it will be easily adopted.

“This biomaterial is based on alginate, a seaweed-derived polysaccharide which is commercially available and used in the food industry.”

“We expect this biomaterial will be reasonably inexpensive and easily implemented, since it does not require any additional synthetic chemistry,” ​he said.

Related topics Bio Developments Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more